page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers j kevin buchi  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in j kevin buchi dir interim president and chief executive officer at impax laboratories inc view full profile are you j kevin buchi claim your profile   sign up for equilar atlas and view j kevin buchis full profile with equilar atlas you can identify corporate executives in j kevin buchis network and community follow changes in j kevin buchis employment and moneyinmotion connect with j kevin buchi through your network of contacts j kevin buchis executive work history current dir interim president and chief executive officer impax laboratories inc past to view j kevin buchis complete executive work history sign up now education northwestern university  kellogg school of management age      j kevin buchis biography j kevin buchi served as our interim president and chief executive officer from december   until march   from august  to december  mr buchi served as president and chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporation formerly nasdaq tlog a clinicalstage biopharmaceutical company tetralogic pharmaceuticals which assets were subsequently acquired by medivir ab in december  prior to his time at tetralogic pharmaceuticals mr buchi served as corporate vice president global branded products of teva pharmaceutical industries ltd nyse teva a pharmaceut  read more j kevin buchi served as our interim president and chief executive officer from december   until march   from august  to december  mr buchi served as president and chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporation formerly nasdaq tlog a clinicalstage biopharmaceutical company tetralogic pharmaceuticals which assets were subsequently acquired by medivir ab in december  prior to his time at tetralogic pharmaceuticals mr buchi served as corporate vice president global branded products of teva pharmaceutical industries ltd nyse teva a pharmaceutical company teva from october  to may  prior to his position at teva mr buchi served as chief executive officer of cephalon inc formerly nasdaq ceph a pharmaceutical company subsequently acquired by teva cephalon from december  to october  and held various positions at cephalon including chief operating officer from january  to december  and chief financial officer from  to  since april  he has served as a director on the board and as a member of the remuneration and nominating committee and audit committee of the board of benitec biopharma ltd nasdaq bntc a biotechnology company headquartered in australia mr buchi has previously served on the board and committees of various pharmaceutical and biotechnology companies including the board and the audit committee of epirus biopharmaceuticals inc formerly nasdaq eprs a biopharmaceutical company from june  to july  the board and the compensation committee of alexza pharmaceuticals inc formerly nasdaq alxa a pharmaceutical company focused on the acute treatment of central nervous system conditions subsequently acquired from january  to june  the board and the audit committee of forward pharma as nasdaq fwp a biotechnology company founded in denmark from december  to may  the board and the audit compensation and nominating and corporate governance committees of stemline therapeutics inc nasdaq stml a clinical stage biopharmaceutical company from march  to may  and the board and audit committee of meslobast limited an australian securities exchange listed biotechnology company from  to  mr buchi received his ba degree from cornell university and a masters of management from the jl kellogg graduate school of management at northwestern university mr buchis extensive experience as a senior executive and board member in the pharmaceutical industry provides the board with unique insights into our business source impax laboratories inc on    sign up for equilar atlas and view j kevin buchis full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like j kevin buchi more specifically youll be able to identify corporate executives in j kevin buchis network and community follow changes in j kevin buchis employment and moneyinmotion connect with j kevin buchi through your network of conections view full profile   search for over  executive profiles bio example j kevin buchi j kevin buchis connections  sign up now to view j kevin buchis  connections » eric l dobmeier chief operating officer seattle genetics inc gail r wilensky board member unitedhealth group incorporated scott m rocklage former acting chief executive officer and director epirus biopharmaceuticals inc andrew l pecora former board member caladrius biosciences inc douglas s boothe president impax generics impax laboratories inc geoffrey m duyk former board member aerie pharmaceuticals inc douglas reed former board member tetralogic pharmaceuticals corporation dennis l winger board member accuray incorporated mark k oki chief financial officer and chief accounting officer vivus inc andrew l busser former board member alexza pharmaceuticals inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla jan koum board member facebook inc philip l milstein board member the marcus corporation × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   impax announces appointment of j kevin buchi to board of directors impax announces appointment of j kevin buchi to board of directors news provided by impax laboratories inc nov    et share this article hayward calif nov   prnewswire  impax laboratories inc nasdaq ipxl announced today that j kevin buchi was appointed to the impax board of directors on november  mr buchi  currently serves as president chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporation we are pleased to welcome kevin to our board said robert l burr chairman of the board of impax laboratories kevin brings a great deal of pharmaceutical experience as an accomplished executive and director he will provide valuable insights and perspective with respect to our operations strategy and corporate governance prior to joining tetralogic pharmaceuticals in august  mr buchi served as corporate vice president of global branded products at teva pharmaceutical industries limited from  to may  before joining teva he was chief executive officer of cephalon inc which was acquired by teva in october  mr buchi joined cephalon in  and held various leadership positions including chief financial officer and chief operating officer before becoming cephalons chief executive officer in december  in addition to being a director of tetralogic pharmaceuticals mr buchi has since  served as a director of benitec biopharma ltd a nasdaq listed biotechnology company headquartered in australia he has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including epirus biopharmaceuticals inc alexza pharmaceuticals inc and forward pharma as mr buchi received his ba degree in chemistry from cornell university and a masters of management degree from the jl kellogg graduate school of management northwestern university  safe harbor statement under the private securities litigation reform act of  to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in revenues and operating income the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner reductions or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the impact of competition the companys ability to sustain profitability and positive cash flows any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements with brand pharmaceutical companies product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numienttm ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys  industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims risks relating to goodwill and intangibles changes in tax regulations the companys ability to manage growth including through potential acquisitions and investments  the risks related to the companys acquisitions of or investments in technologies products or businesses the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact  on cash flow available for operations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwise about impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through its impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platforms and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information please visit the companys web site at wwwimpaxlabscom company contactsmark donohueinvestor relations and corporate communications wwwimpaxlabscom   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxannouncesappointmentofjkevinbuchitoboardofdirectorshtml source impax laboratories inc related links httpwwwimpaxlabscom dec    et preview impax laboratories announces leadership transition nov    et preview impax to present at the th annual piper jaffray healthcare conference my news release contains wide tables view fullscreen also from this source jul    et impax announces fda approval of its ab rated generic concerta® jul    et impax announces fda approval and launch of additional strengths explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read impax announces appointment of j kevin buchi to board of directors news provided by impax laboratories inc nov    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search j kevin buchi be mba cpa executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of impax laboratories inc snapshotpeople  overviewboard memberscommittees executive profile j kevin buchi be mba cpadirector impax laboratories incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background mr j kevin buchi be mba cpa served as interim chief executive officer and interim president of impax laboratories inc from december   to march   mr buchi served as the chief executive officer and president of tetralogic pharmaceuticals corporation from august   to december   he served as corporate vice president of global branded products at teva pharmaceutical industries limited from  to may  he served as the chief executive  officer of cephalon inc from december   to october  he served as the chief operating officer of cephalon inc from january   to december  he served as the chief financial officer of cephalon inc from april  to january   and also served as its principal accounting officer until january   he served as the head of business development of cephalon inc since  he served as an executive vice president of cephalon inc from february  to january   he served as senior vice president of cephalon inc from april  to  controller since march  and held several financial positions mr buchi served in a number of financial positions at ei du pont de nemours and company from  to  he was responsible for finance accounting business development and information systems and involved in raising significant financing for cephalon inc he helped and guided cephalon through several financings product and company acquisitions and in the development and execution of successful growth strategies he served positions at pricewaterhousecoopers he was a synthetic organic chemist for the eastman kodak company mr buchi joined cephalon in march  he has helped guide cephalon through several financings product and company acquisitions and in the development and execution of successful growth strategies he has been director of teva pharmaceuticals australia pty ltd since may  and chemgenex pharmaceuticals ltd since june  he has been director at impax laboratories inc since november   he served as a director of tetralogic pharmaceuticals corporation from august  to december   he served as director of alexza pharmaceuticals inc from january   to june   mr buchi served as an independent director at epirus biopharmaceuticals inc since july  until july   he served as an independent director of stemline therapeutics inc from march   to may   mr buchi served as a director of benitec biopharma ltd a nasdaq listed biotechnology company headquartered in australia since  he served as a nonexecutive director of mesoblast limited from december   to may   he served as a director of forward pharma as since december  until may   he served as a director of celator pharmaceuticals inc since july   cephalon inc since december   and arana therapeutics pty limited since may  he served as a member of life sciences advisory board at safeguard scientifics inc he served as a director of aptose biosciences inc formerly lorus therapeutics inc since december  he served as a director of encysive pharmaceuticals inc from june   to june  he is a certified public accountant mr buchi holds a ba in chemistry from cornell university in  and an mba degree from the jl kellogg graduate school of management northwestern university in read full background corporate headquarters  huntwood avenuehayward california united statesphone fax  board members memberships presentdirectorteva pharmaceuticals australia pty ltdpresentdirectorchemgenex pharmaceuticals ltdpresentdirectorimpax laboratories inc education ba cornell universitymba jl kellogg school of management northwestern university other affiliations safeguard scientifics inccephalon incaptose biosciences incteva pharmaceutical industries limitedencysive pharmaceuticals incteva pharmaceuticals australia pty ltdchemgenex pharmaceuticals ltdcornell universitycelator pharmaceuticals incjl kellogg school of management northwestern universitystemline therapeutics inctetralogic pharmaceuticals corporationmesoblast limitedalexza pharmaceuticals incforward pharma asepirus biopharmaceuticals inc annual compensation salarytotal annual compensation stocks options restricted stock awardsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationron cohen mdfounder chief executive officer president and directoracorda therapeutics inckarthur p bedrosian jdceo  directorlannett company incmhari shanker bhartia btechcochairman and managing directorjubilant life sciences limitedronald m lombardi chairman president  ceoprestige brands holdings inckdaniel j abdunnabi chief executive officer president and directoremergent biosolutions inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact impax laboratories inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close   j kevin buchi  linkedin linkedin main content starts below j kevin buchiceo at tetralogic pharmaceuticalslocationmalvern pennsylvaniaindustrybiotechnologycurrenttetralogic pharmaceuticals impax laboratories benitec biopharmpreviousteva pharmaceuticals cephaloneducationnorthwestern university  kellogg school of management connectionsview j kevin’s full profile its freeyour colleagues classmates and  million other professionals are on linkedinview j kevin’s full profileexperienceceotetralogic pharmaceuticalspresentmember board of directorsimpax laboratories benitec biopharm – present  yearformer ceo cephalon inc corp vp global branded product teva ceo tetralogic pharma interim ceo impax labscorporate vp global branded productsteva pharmaceuticalsoctober  – may   monthsceocephalondecember  – october   monthscoocephalonjanuary  – december   yearcfocephalon – december   yearseducationnorthwestern university  kellogg school of managementmaster of management accounting and financemaster of management accounting and finance – cornell universitybachelor of arts ba chemistrybachelor of arts ba chemistry – view j kevin’s full profile tosee who you know in commonget introducedcontact j kevin directlyview j kevin’s full profileview this profile in another languageenglishgermanpeople also viewedchristopher cashmanjean jacques bienaimejeanpierre jp sakeyjohn gillceo at tetralogic pharmaceuticalscarol s marchionevice president regulatory affairs at innocoll pharmaceuticalssherri carenzoregulatory affairs and quality control manager at tetralogic pharmaceuticalsjustin nelsonbusiness process owner  finance at teva pharmaceuticalsjeffrey d marrazzochief executive officer spark therapeuticslee guerinterritory business manager at incytefrank baldinochairman and ceo at cephalonpublic profile badgeinclude this linkedin profile on other websitesview profile badgessearch by nameover  million professionals are already on linkedin find who you knowfirst namelast nameexample jeff weinerlinkedin member directoryabcdefghijklmnopqrstuvwxyzmorebrowse members by country ipxl j kevin buchi insider trades for impax laboratories inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close impax laboratories inc nasdaq ipxl go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus impax laboratories inc after hours  quotes are delayed by  min jul    pm ipxl quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual j kevin buchi mr j k buchi is on the board of directors at impax laboratories inc benitec biopharma ltd and chemgenex pharmaceuticals pty ltd mr buchi was previously employed as an independent director by epirus biopharmaceuticals inc an independent director by zalicus inc president chief executive officer  director by tetralogic pharmaceuticals corp an independent director by alexza pharmaceuticals inc an independent director by forward pharma as an independent director by stemline therapeutics inc vice presidentglobal branded products by teva pharmaceutical industries ltd nonexecutive director by mesoblast ltd and chief executive officer  director by cephalon inc he also served on the board at epirus biopharmaceuticals inc old arana therapeutics ltd celator pharmaceuticals inc encysive pharmaceuticals inc and lorus therapeutics inc he received his undergraduate degree from cornell university and a graduate degree from kellogg school of management transactions date shares transaction value     award at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr paul m bisaro president chief executive officer  director mr andrew schaschl senior vice presidentglobal operations mr bryan m reasons chief financial officer  senior vpfinance dr vishal k gupta cso senior vice presidentresearch  development mr jeffrey d nornhold senior vice presidenttechnical operations mr douglas s boothe presidentgenerics division mr goff baker senior vice presidentglobal quality mr brandon smith senior vpcorporate development  strategy mr michael j nestor presidentimpax pharmaceuticals division ms deborah m penza chief compliance officer  senior vice president mr j kevin buchi director mr richard a bierly director mr mark j donohue vpinvestor relations  communications ms donna m hughes senior vice presidenthuman resources mr mark a schlossberg secretary senior vice president  general counsel mr robert l burr chairman ms janet s vergis independent director mr peter r terreri independent director dr leslie z benet independent director dr allen y chao independent director ms mary k pendergast independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower ptwothirds of us investors think stocks are overvalued loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  impax laboratories inc  impax announces appointment of j kevin buchi to board of directors investor relations  media center  careers  contact homeour companyour experienceour divisionsmedia center media center media center media center press releases download library media centerpress releasesdownload librarymedia center home»media center»press releases»press release press release  back impax announces appointment of j kevin buchi to board of directors  download this press release pdf hayward calif nov   prnewswire  impax laboratories inc nasdaq ipxl announced today that j kevin buchi was appointed to the impax board of directors on november  mr buchi  currently serves as president chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporation we are pleased to welcome kevin to our board said robert l burr chairman of the board of impax laboratories kevin brings a great deal of pharmaceutical experience as an accomplished executive and director he will provide valuable insights and perspective with respect to our operations strategy and corporate governance prior to joining tetralogic pharmaceuticals in august  mr buchi served as corporate vice president of global branded products at teva pharmaceutical industries limited from  to may  before joining teva he was chief executive officer of cephalon inc which was acquired by teva in october  mr buchi joined cephalon in  and held various leadership positions including chief financial officer and chief operating officer before becoming cephalons chief executive officer in december  in addition to being a director of tetralogic pharmaceuticals mr buchi has since  served as a director of benitec biopharma ltd a nasdaq listed biotechnology company headquartered in australia he has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including epirus biopharmaceuticals inc alexza pharmaceuticals inc and forward pharma as mr buchi received his ba degree in chemistry from cornell university and a masters of management degree from the jl kellogg graduate school of management northwestern university  safe harbor statement under the private securities litigation reform act of  to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in revenues and operating income the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner reductions or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the impact of competition the companys ability to sustain profitability and positive cash flows any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements with brand pharmaceutical companies product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numienttm ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys  industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims risks relating to goodwill and intangibles changes in tax regulations the companys ability to manage growth including through potential acquisitions and investments  the risks related to the companys acquisitions of or investments in technologies products or businesses the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact  on cash flow available for operations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwise about impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through its impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platforms and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information please visit the companys web site at wwwimpaxlabscom company contactsmark donohueinvestor relations and corporate communications wwwimpaxlabscom   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxannouncesappointmentofjkevinbuchitoboardofdirectorshtml source impax laboratories inc related links products and pipeline leadership contact investor toolkit email page rss feeds email alerts copyright   impax laboratories inc all rights reserved sitemap  legal and copyright disclaimer name first name is required email email is required comments enter text   enter the code shown above  invalid powered by q inc  impax announces appointment of j kevin buchi to board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health careimpax announces appointment of j kevin buchi to board of directorspr newswirenovember  reblogsharetweetsharehayward calif nov   prnewswire  impax laboratories inc ipxl announced today that j kevin buchi was appointed to the impax board of directors on november  mr buchi  currently serves as president chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporationwe are pleased to welcome kevin to our board said robert l burr chairman of the board of impax laboratories kevin brings a great deal of pharmaceutical experience as an accomplished executive and director he will provide valuable insights and perspective with respect to our operations strategy and corporate governanceprior to joining tetralogic pharmaceuticals in august  mr buchi served as corporate vice president of global branded products at teva pharmaceutical industries limited from  to may  before joining teva he was chief executive officer of cephalon inc which was acquired by teva in october  mr buchi joined cephalon in  and held various leadership positions including chief financial officer and chief operating officer before becoming cephalons chief executive officer in december in addition to being a director of tetralogic pharmaceuticals mr buchi has since  served as a director of benitec biopharma ltd a nasdaq listed biotechnology company headquartered in australia he has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including epirus biopharmaceuticals inc alexza pharmaceuticals inc and forward pharma asmr buchi received his ba degree in chemistry from cornell university and a masters of management degree from the jl kellogg graduate school of management northwestern university safe harbor statement under the private securities litigation reform act of to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in revenues and operating income the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner reductions or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the impact of competition the companys ability to sustain profitability and positive cash flows any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements with brand pharmaceutical companies product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numienttm ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys  industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims risks relating to goodwill and intangibles changes in tax regulations the companys ability to manage growth including through potential acquisitions and investments  the risks related to the companys acquisitions of or investments in technologies products or businesses the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact  on cash flow available for operations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwiseread moreabout impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through its impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platforms and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information please visit the companys web site at wwwimpaxlabscomcompany contactsmark donohue investor relations and corporate communications   wwwimpaxlabscom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxannouncesappointmentofjkevinbuchitoboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextkeycorp ceo beth mooney says economic stimulus will have a coiledspring effect on banks capitalcnbcweyerhaeuser will spend millions to fix stinky wood in homespuget sound business journalcoming soon to amazon alexaenabled kenmore fridges and washing machinesdigital trendsmarissa mayer wants ceo atop her resume again after end of yahoo but uber silent so far reportsiliconbeatsoftbank ceo sees massive data ai as key to future advancesassociated presstrump administration pulls health law help in  citiesassociated pressshortsellers have lost  billion betting against this years hottest tech stocksyahoo financei tried the atkins on steroids diet for  months — and it made me feel invinciblebusiness insiderglaxosmithklines new ceo prepares to trim drug pipelinereutersaetna ceo bertolini how tech plays into the future of healthcareyahoo finance videostocks back off from record highsyahoo financethe cia director just dropped some heavy hints that the us is looking into regime change in north koreabusiness insiderthe pizzamaking robots that want to change the worlddavid pogueone month after tim tebows ridiculed promotion he is on firebusiness insideraetna ceo bertolini why he pays his employees to sleepyahoo finance videowhat harlem thinks about whole foods coming to the neighborhoodyahoo financesix months into americas nightmare how likely is trumps impeachment  richard wolfferon the nightmare is only for the liberals and i hope it gets worse every day for them president trump is doing exactly what we elected to dojoin the conversation  k encysive pharmaceuticals appoints j kevin buchi to board of directors english français register sign in encysive pharmaceuticals appoints j kevin buchi to board of directors june    et  source encysive pharmaceuticals inc houston june   primezone  encysive pharmaceuticals nasdaqency today announced that j kevin buchi  has been elected to the companys board of directors and appointed to serve on the audit committee mr buchis appointment brings to  the number of directors mr buchi is senior vice president finance and chief financial officer of cephalon inc mr buchi has helped guide cephalon through several financings product and company acquisitions and in the development and execution of successful growth strategies prior to cephalon mr buchi held positions at ei dupont de nemours and company pricewaterhousecoopers and eastman kodak co mr buchi holds a ba in chemistry from cornell university and an mba from kellogg graduate school of management at northwestern university he is also a certified public accountant kevins extensive experience and success in the biotechnology industry will be invaluable as we move closer towards the commercialization of thelintm our lead product candidate in phase iii development for pulmonary arterial hypertension said john m pietruski chairman of the board of encysive pharmaceuticals we are pleased to welcome kevin to the board and will look to his expertise in the coming months and years about encysive pharmaceuticals encysive pharmaceuticals inc a biopharmaceutical company focused on the discovery development and commercialization of novel drugs is recognized for our expertise in small molecule drug development and vascular biology argatroban our first fdaapproved product is being marketed by glaxosmithkline for heparininduced thrombocytopenia encysive pharmaceuticals is in phase iii development of the endothelin antagonist thelin for pulmonary arterial hypertension our majorityowned affiliate revotar biopharmaceuticals ag is in phase ii development with the selectin antagonist bimosiamose in asthma psoriasis and atopic dermatitis encysive pharmaceuticals has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases to learn more about encysive pharmaceuticals please visit our web site wwwencysivecom this press release contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended these forwardlooking statements are subject to certain risks trends and uncertainties that could cause actual results to differ materially from those projected among those risks trends and uncertainties are timing and cost of our clinical trials attainment of research and clinical goals and milestones of product candidates attainment of required government approvals sales levels of our products and availability of financing and revenues sufficient to fund development of product candidates and operations in particular careful consideration should be given to cautionary statements made in the various reports encysive pharmaceuticals including as texas biotechnology corporation has filed with the securities and exchange commission the company undertakes no duty to update or revise these forwardlooking statements the encysive pharmaceuticals inc company logo can be found at httpmediaprimezonecomprssinglepkgid media bmc communications daniel budwick   ext  investors encysive pharmaceuticals ann tanabe   the trout group hershel berry   related articles other press releases by encysive pharmaceuticals inc update  encysive pharmaceuticals reports fourth quarter and year end  financial results march    encysive pharmaceuticals reports fourth quarter and year end  financial results march    encysive pharmaceuticals announces date change for reporting  yearend financials february    encysive pharmaceuticals launches thelin sitaxentan sodium in sweden january    encysive pharmaceuticals launches thelin sitaxentan sodium in belgium and luxembourg january     other news releases in directors and officers in the last  days profile encysive pharmaceuticals inc   subscribe via rss  subscribe via atom  javascript houston texas united states   httpwwwencysivecom contact data media bmc communications daniel budwick   ext  investors encysive pharmaceuticals ann tanabe   the trout group hershel berry   media files encysive pharmaceuticals inc logo url  copy the link below formats available original medium small tags pharmaceuticals biotechnology management changes newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft loading your search results  peoplelookercom updating data on  live please help us narrow down your search all states alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming im not sure please enter a full name please help us narrow down your search first name please enter first name last name please enter last name people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again j kevin buchi  wowcom  web results aol search skip over navigation search the web web images images reference reference we found kevin buchi  peoplelookercom ad · wwwpeoplelookercom  kevin buchis phone  address  age  more search free uncover potential relatives photos  videos historical deeds location history email address monitor social info web results j kevin buchi be mba cpa executive profile  biography  httpswwwbloombergcomresearchstocksprivatepersonasp mr j kevin buchi be mba cpa served as interim chief executive officer and interim president of impax laboratories inc from december   to  j kevin buchi malvern pennsylvania on linkedin httpswwwlinkedincominjkevinbuchi view j kevin buchi’s professional profile on linkedin linkedin is the worlds largest business network helping professionals like j kevin buchi discover inside  j kevin buchi  executive bio compensation history and  peopleequilarcombiojkevinbuchitetralogicpharmaceuticals view j kevin buchi dir interim president and chief executive officer at impax laboratories inc hayward ca executive profile on equilar atlas to see current  j kevin buchi  browse jobs by salary ranges  salarycom wwwsalarycomjkevinbuchisalarybonusstockoptionsfortetra salary bonuses stock options stock awards and other compensation for j kevin buchi  president chief executive officer and director at tetralogic pharmaceuticals mr j kevin buchi  executive bio  compensation history executivesfindthecompanycomlmrjkevinbuchi find compensation and employment information for mr j kevin buchi tetralogic pharmaceutical including salary stock awards and previous employers alexza pharmaceuticals appoints j kevin buchi to its  httpswwwthestreetcomstoryalexzapharmaceuticals mountain view calif jan   prnewswire  alexza pharmaceuticals inc nasdaq alxa announced today that j kevin buchi has been appointed to its board of  impax announces appointment of j kevin buchi to board of  investorsimpaxlabscommediacenterpressreleasespressrelease impax laboratories inc nasdaq ipxl announced today that j kevin buchi was appointed to the impax board of directors on november   mr buchi  currently  compensation information for j kevin buchi  interim  wwwsalarycomjkevinbuchisalarybonusstockoptionsforimpax salary bonuses stock options stock awards and other compensation for j kevin buchi  interim president and chief executive officer at impax laboratories inc how  ipxl j kevin buchi insider trades for impax laboratories inc wwwmarketwatchcominvestingstockipxlinsiderspid ipxl stock quote and financial news from the leading provider and awardwinning marketwatchcom leadership  impax laboratories inc wwwimpaxlabscomourcompanyleadership gupta held several leadership positions with increasing responsibilities over almost  years at alzajnj dr gupta made significant contributions to  j kevin buchi we found kevin buchi  peoplelookercom ad · wwwpeoplelookercom  kevin buchis phone  address  age  more search free uncover potential relatives photos  videos historical deeds location history email address monitor social info next answers kevin j dooley marshall scott poole andrew h van de ven and kevin dooley  organizational change and innovation theory and methods for research new oxford more kevin j miyazaki kevin j miyazaki is a graphic designer photographer and educator based in milwaukee wisconsin he attended drake university in des moines iowa more j kevin dorsey j kevin dorsey born new york new york was the dean provost and professor of internal medicine of the southern illinois university school of more news results kevin j bishop saving the world this aint hell but you can see  jul  chief tango send us a link to the story of national guard staff sergeant and alabama corrections captain kevin j bishop who was awarded the soldier’s more iverify appoints kevin j thomas as chief automotive  jul  we welcome a cmo of kevin’s caliber to our team representing iverify’s commitment to its strategy of growth and pursuing new market opportunities more kevin schaul and kevin uhrmacherpost dc sports bog   hrs ago after six months in office president trump remains behind on filling the government with political appointees to oversee core government functions and more search the web  aol inc all rights reservedprivacy   terms of use   about our ads   preferences   contact us   powered by bing™ part of the aol search network